Navigation Links
Adnexus Therapeutics Announces Presentation at the American,Association for Cancer Research (AACR) on Clinical Product,Candidate, CT-322

WALTHAM, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - Adnexus(TM) Therapeutics, Inc. today announced the presentation of the abstract "CT-322: A specific VEGFR-2-blocking protein therapeutic agent with activity in preclinical tumor models comparable to pan-specific tyrosine kinase receptor inhibitors sunitinib and sorafenib" at the American Association for Cancer Research (AACR) 2007 annual meeting in Los Angeles, CA. The lead author is Irvith Carvajal, Ph.D., with Eric Furfine, Ph.D., senior vice president of research and preclinical development at Adnexus, presenting at the meeting.

CT-322 is a mono-specific blocker of the tyrosine kinase receptor, VEGFR-2, and blocks its activation by all known extracellular ligands; VEGF-A, VEGF-C, and VEGF-D. VEGFR-2 activation is the primary driver of tumor angiogenesis. In preclinical tumor models, CT-322 was compared to two approved pan-kinase inhibitors sunitinib and sorafenib. CT-322, sunitinib, and sorafenib each demonstrated comparable tumor growth suppression; however, CT-322 was better tolerated in the animal models.

"Our results suggest that 'pan-specific' kinase inhibitors may not offer improvement in anti-angiogenic induced tumor suppression over an extracellular, mono-specific blocker of VEGFR-2," commented Dr. Furfine. "CT-322's high affinity and selectivity for VEGFR-2 achieved comparable anti-tumor effect to molecules that inhibit a broad range of kinases."

"As cancer therapy evolves, the importance of efficacy, safety and tolerability of anti-angiogenic agents are becoming more pronounced due to the desire for combination therapy as well as longer duration of anti-angiogenic therapy," commented John Mendlein, Ph.D., chief executive officer of Adnexus. "We continue to extend our understanding of the VEGFR-2 pathway in tumor settings and its activation by VEGF-A, C and D. We are very encouraged by the emerging CT-322 Phase 1 data, and we look forward
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:4/17/2015)... April 17, 2015 ASSESS shows ...   is a viable alternative to tumour biopsy   ... all patients with advanced NSCLC   AstraZeneca today ... plasma circulating tumour DNA (ctDNA) testing for epidermal growth factor ... non-small cell lung cancer (NSCLC) in clinical practice. [ ...
(Date:4/17/2015)... YORK , April 17, 2015  Over the next ... to continue to grow, with ArcView predicting that 14 more ... legalize medical marijuana. The U.S. market for legal cannabis grew ... billion in 2013. Analysts project the market could grow more ... assuming more states soften their stance on marijuana. ...
(Date:4/17/2015)... 2015 Research and Markets ( ... "The Corporate Reputation of Pharma - The ... report to their offering. The ... now in its fourth edition. This report contains ... For each annual Corporate Reputation report, the author ...
Breaking Medicine Technology:"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2
(Date:4/18/2015)... 18, 2015 Review of Ophthalmology magazine ... ‘Strategies for Success’ program for cataract surgeons attending the ... San Diego, where eye surgeon Jeffrey L. Martin, MD ... event. Dr. Martin is the Managing Partner of North ... chose Dr. Martin to lead this year’s discussion on ...
(Date:4/18/2015)... April 18, 2015 Lowcostcarinsuranceprice.com has released ... rates have on auto insurance prices . ... rates of vehicle theft may have to pay more ... liability auto insurance policies can also offer protection against ... now be compared online on a single website: ...
(Date:4/18/2015)... 18, 2015 Patients who undergo radiation ... mesothelioma later in life, but the disease is likely ... is unrelated to radiation. Surviving Mesothelioma has just posted ... Click here to read it now. , ... cases of 45 patients who had both a hematologic ...
(Date:4/18/2015)... In the past few weeks, TheBeautyPlace.com has been undergoing ... to run maintenance on our shipping facilities to update ... PR Director. "It disrupted our regular shipping schedule but ... on track after having completed the maintenance." , Now, ... which has not allowed some calls to come in ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 On April 14th, ... Threat Report , which they say, “exposes a tactical shift ... new malware variants were introduced in 2014 - almost a ... Zero Day threats to be identified and patched by prominent ... abundantly clear that doing business in a digital world can ...
Breaking Medicine News(10 mins):Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Temporary Number Available 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5
... is available in French . , Pediatric ... a massive boost today, following the Cole Foundation,s announcement that ... 10 Universit de Montral and four McGill University young scientists. ... and lymphomas in people under the age of 25, and ...
... , TUESDAY, May 17 (HealthDay News) -- A ... affect production of the pregnancy hormone progesterone and may be ... The Johns Hopkins University team looked at more than ... and identified nine who had the variation of the scavenger ...
... four years of remarkable progress including pioneering discoveries ... Medical Research Institute (SMRI) today announced that it will ... Institute,s Stanley Center for Psychiatric Research. Launched ... the SMRI, the Stanley Center brings together scientists from ...
... Mozes HealthDay Reporter , MONDAY, May 16 (HealthDay News) ... elevate "bad" cholesterol levels, and may in fact prompt a very ... , The finding comes from a six-month examination of the ... of healthy people in England. , , "The issue is that ...
... It is important for health care providers to report health ... there is evidence of a reluctance to share patient data ... privacy and provider confidentiality. Dr. Khaled El-Emam and his research ... protocol and system that would solve this problem. The ...
... by the UK journal Reproductive Health Matters shows ... the development of a vast illegal private sector with no ... became illegal in the late 1980s the number of abortions ... trade in abortions is, however, flourishing, with abortion providers advertising ...
Cached Medicine News:Health News:Cole Foundation injects $700,000 into childhood cancer research 2Health News:Gene Variation May Explain Some Female Infertility Cases 2Health News:Grant extends funding for the Broad's Stanley Center for Psychiatric Research 2Health News:Selenium Supplements Might Give Modest Benefit Against Cholesterol 2Health News:Selenium Supplements Might Give Modest Benefit Against Cholesterol 3Health News:CHEO Research Institute develops secure protocol for data disclosure 2Health News:Abortions generate $95 million a year for Polish doctors as women use illegal private sector 2
The vertical needle holder conveniently positions 20 needles vertically in numbered positions for easy loading....
... is a vacuum driven device designed to pull prostate ... Seeds are drawn into the clear tube tip by ... piece to create the vacuum. The prescribed sequence of ... tube tip before being placed into the needle. These ...
MT-BT-5011-25 Prostate seeding needle (set of 25 unloaded needles).,MT-BT-5011-P Prostate seeding needle, pre-plugged and pre-sterilized, unloaded or for use with MEDTECs ASAP™ pre-load seedin...
MT-BT-5001-25 prostate seeding needle (set of 25 unloaded needles).,MT-BT-5001-P prostate seeding needle, pre-plugged and pre-sterilized, unloaded or for use with MEDTECs ASAP™ pre-load seeding...
Medicine Products: